Kornimate/medical-research-clean huggingface dataset:
the stool microbiome of treated and untreated ibs (irritable bowel syndrome) patients

Conditions: Irritable Bowel Syndrome

Summary: irritable bowel syndrome (ibs) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. alterations in the gut microbiome are at the center of ibs, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. however, the characteristics and functions of these metabolites remain unknown to date. the two main mechanisms invoking ibs development and flares include 1) an increase in luminal water content due to malabsorption of small molecules and 2) incrementation of colon gas production generated by the fermentation of small molecules by gut bacteria.yet to date, a person-specific elucidation of the specific small molecules and bacteria driving ibs, and their downstream effects on the human gut epithelium remain unknown. over the past years, it became evident that dietary regimes, and their interactions with the intestinal microbiome, are at the center of ibs symptom generation and alleviation. the most widely used dietary intervention is a highly restrictive diet, the low-fermentable oligo-saccharides di-saccharides mono-saccharides and polyols (fodmap) diet, based on avoidance of multiple food items that contain available fermentable molecules. the low-fodmap diet remains an effective line of treatment for ibs patients, yet due to its complexity and unhealthy nature, it remains a last line of treatment and fails to impact the majority of ibs patients.


Eligibility criteria:
inclusion criteria: * male and female * age - 18-70 exclusion criteria: * consumption of antibiotics 2 months prior to the first day of the experiment. * consumption of probiotic supplements 1 month prior to the first day of the experiment. * type 1 or type 2 diabetes diagnosis. * pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study. * chronic disease - to the discretion of the study doctor. * cancer and recent anticancer treatment. * psychiatric disorders - to the discretion of the study doctor. * ibd (inflammatory bowel diseases). * alcohol or substance abuse. * bmi \> 35.
ebv-tcr-t cells for eb virus infection after hsct

Conditions: EBV Emia and EBV Positive PTLD After Allogenic HSCT

Summary: this is a single center, single arm, open-label, phase i study to evaluate the safety and efficacy of ebv-tcr-t cells in patients with eb virus infection after hsct.

ebv infection is a common virus infection of hsct, and which is highly related with the failure of transplantation and survival time of transplant patients. to evaluate the safety and efficacy of allogenic ebv-tcr-t cell therapy in subjects with ebv infection, patients with ebv emias or ebv positive ptld will be enrolled, and donor derived ebv-tcr-t(hla-a\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 ebv-tcr-t cells. the ebv dna copies and ebv-tcr-t cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).

Eligibility criteria:
inclusion criteria: 1. age 1-70 years, including boundary values, gender unlimited; 2. the ebv dna copies number of allogenic hsct patients with ebv infection (ebv emia and ebv positive ptld) still did not decrease，after treated with lower dosage of immunosuppressants，or antiviral therapy or rituximab（rituxan）； 3. allogenic hsct patients could not tolerate the antiviral therapy and / or rituximab（rituxan）； 4. the ebv-positive diagnosis criteria: ebv dna copy number\>1000 copies/ ml, or the tissue ebv-eber pathological result is positive, the diagnosis of ptld was based on the diagnostic criteria of who 2016； 5. estimated life expectancy ≥ 3 months； 6. ecog 3 ； 7. patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures. exclusion criteria: 1. patients with active agvhd iii-iv and / or mild and severe cgvhd; 2. received cell therapy such as dli,ctl,car-t or participated in any other clinical study of drugs and medical devices before 30 days of enrollment； 3. pregnant or lactating women; 4. intracranial hypertension or confusion; respiratory failure; disseminated intravascular coagulation; 5. patients with organ failure: * heart: nyha heart function grade iv; * liver: grade c that achieves child-turcotte liver function grading; * kidney: kidney failure and uremia; * lung: symptoms of respiratory failure; * brain: a person with a disability; 6. the researchers found that it was unsuitable for the recipients to be enrolled.
early ultrasound and maternal biochemical markers to evaluate the risk of down syndrome during the first trimester

Conditions: Down Syndrome

Summary: the aim of the study is to evaluate the risk of down syndrome during the first trimester of the pregnancy. the risk assessment is evaluated using early ultrasound and maternal biochemical markers.


Eligibility criteria:
inclusion criteria: * female \> 18 years old * pregnant exclusion criteria: * maternal age \< 18 years old, twin pregnancy

Keywords: nucal translucency down syndrome mss risk assessment
fli normative study

Conditions: Hearing Loss

Summary: single center, cross sectional observational research design to collect normative data on the acquisition of listening skills in normally-hearing children aged 0-6 years of age.

the primary objective is the assessment of listening skill acquisition in normally-hearing children aged between 0 and 6 years with the functional listening index - paediatric (fli-p). the fli-p has been developed to address a substantial gap in the current tools available to measure the development of auditory skills in children. the fli-p provides a measure of listening skills acquisition in children from birth to six years of age (0 - 72 months). the fli-p will be administered by an investigator who has received appropriate training in its use or completed by parents/caregivers themselves. the fli-p assessment will be conducted using an application running on a personal computer, tablet or online device. there are no specific medical or surgical procedures involved in this clinical investigation and the fli-p is a non-interventional application.

Eligibility criteria:
inclusion criteria: * children aged between 0 and 6 years of age. * pass on the newborn hearing screen status conducted during the new south wales statewide infant screening - hearing (swish) program. * no current parental or professional concern regarding hearing status. exclusion criteria: * pre-existing diagnosis of additional needs. * unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations of the study. * unwillingness or inability of the subject to comply with all investigational requirements.

Keywords: functional listening index
meta-analysis of stannous fluoride dentifrice and the effects on dentine hypersensitivity

Conditions: Dentine Hypersensitivity

Summary: the aim of this 11 study analysis was to compare the effect of bioavailable stannous fluoride (snf2) on dentine hypersensitivity versus a positive or negative control dentifrice.


Eligibility criteria:
subjects were excluded from this study for the following reasons; * severe periodontitis * at discretionary of the principal investigator
comparison between transvaginal mesh and traditional surgery for pelvic organ prolapse

Conditions: Vaginal Prolapse

Summary: pelvic organ prolapse is characterized by a lack of pelvic floor support causing the pelvic organs and vaginal walls to protrude. for decades, suture repair techniques have been the primary choice of surgical treatment when indicated. traditional surgical techniques are frequently associated with unsatisfying anatomical recurrence rates and it is plausible that inherently weak, or damaged, pelvic floor supportive tissues need to be reinforced by a permanent support to avoid the high rates of recurrences commonly described using traditional techniques. over the years sporadic attempts have been made to introduce novel surgical techniques using a variety of biomaterials with varying success. despite a lack of clinical safety data, or compelling clinical evidence demonstrating that it improves outcomes compared to traditional suture techniques, use of biomaterials in pelvic reconstructive surgery has become widespread in just a few years . it is likely that biomaterials need to be "anchored" in tissues not afflicted by the disease, in order to provide the intended pelvic floor support. this has given rise to transvaginal surgical techniques using a transobturator approach passing the mesh through the arcus tendineous fascia pelvis, or the sacrospinous ligaments through a transgluteal approach. short term data from concluded and on-going safety assessments of these techniques has provided promising results and satisfying clinical outcomes. the aim of the present study is to compare anterior mesh repair (prolift®) with traditional suture repair in a randomised trial.


Eligibility criteria:
inclusion criteria: * reproductive years in the past (biologically or reproductive decision) * prolapse of the anterior vaginal wall ≥popq-stadium ii * prolapse specific pelvic symptom * being able to make an informed consent on participation * physically and cognitive capable of participating in the required follow-up * no other pelvic floor surgery performed at the time of anterior repair * no exclusion criteria fulfilled exclusion criteria: * previous or current pelvic organ cancer (regardless of treatment) * severe rheumatic disease * insulin treated diabetes mellitus * connective tissue disorders (sle, sjögrens syndrome, marfans syndrome, ehlers danhlos, collagenosis, polymyositis eller rheumatic myalgia) * current systemic steroid treatment

Keywords: vagina prolapse anterior vaginal wall prolapse
heme oxygenase (ho) activity and adenosine induced vasodilation

Conditions: Atherosclerotic Cardiovascular Disease

Summary: the purpose of this study is to determine whether heme oxygenase 1 induction by heme arginate treatment is of influence on adenosine induced vasodilation in healthy individuals.


Eligibility criteria:
inclusion criteria: * at least 18 and no older than 65 on the day of first dosing * healthy * quetelet index (body mass index) of 18 to 30 kg/m2 * in general, results of haematology and chemistry should be within the laboratory's reference ranges. determinants of renal and hepatic function should be within twice the upper limit of normal range. exclusion criteria: * documented history of sensitivity / idiosyncrasy to medicinal products or excipients * history of smoking within the past year * history of or current abuse of drugs, alcohol and/or solvents * current use of any (over the counter) medication potentially influencing heme oxygenase or the cardiovascular system * inability to understand the nature and extent of the trial and the procedures required * participation to a drug trial within 60 days prior to the first dose * febrile illness within 3 days before the first dose * heterozygosity (ls) or homozygosity (ll) with regard to the number of gt repeats in the ho-1 promoter region
efficacy and immunological evaluation of telitacicept and low dose il2 in the treatment of systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study was to explore the clinical and immunological efficacy of telitacicept and low dose il-2 on systemic lupus erythematosus.

given that telitacicept and low dose il2 have been widespreadly applied in the treatment of systemic lupus erythematosus, this study designed a randomised, single center, prospective study to investigate the effects and safety of combined utilization of telitacicept and low dose il-2. 160mg telitacicept and 1 million iu il2 were regularly administered according to different circumstances. then, the investigators evaluated the improvement of clinical and laboratory indexes and monitored the changes of immune cell subsets and cytokines.

Eligibility criteria:
inclusion criteria: 1. male or female \>18 years of age at screening visits 2. patients meet the american-european consensus group 2002 classification criteria of sle. 3. the patient must be informed in writing of the consent to participate in the trial and the patient is expected to be able to comply with the requirements of the study follow-up plan and other protocols. 4. dosing of antimalarials, prednisone or equivalent, cholinergic stimulants, and topical cyclosporine required to be stable for at least 4 weeks before screening and during study; maximum doses allowed: * hydroxychloroquine, 400 mg/day; * prednisone, 10 mg/day exclusion criteria: any subject meeting any of the following criteria should be excluded: 1. laboratory abnormality: • hb≤9 g/dl • neutrophil 10 mg/d) within 1 month. 2. serious complications: including heart failure (≥ new york heart association (nyha) class iii), renal insufficiency (creatinine clearance ≤ 30 ml/min), liver dysfunction (serum alanine transaminase (alt) or aspartate aminotransferase (ast) greater than three times the upper limit of normal, or total bilirubin greater than normal upper limit. 3. known allergies, hyperreactivity or intolerance of tofacitinib or its excipients. 4. have a serious infection needing hospitalization (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, eb virus, tuberculosis infection), or use intravenous antibiotics to treat infection in 2 months before the enrollment. 5. infection with hiv (hiv antibody positive serology) or hepatitis c (hep c antibody positive serology). if seropositive, it is recommended to consult a doctor who has expertise in treating hiv or hepatitis c virus infection. 6. any known history of malignancy in the past 5 years (except for nonmelanoma skin cancer, non-melanoma skin cancer or cervical tumor without recurrence within 3 months after surgical cure prior to the first study preparation). 7. uncontrolled mental or emotional disorders, including a history of drug and alcohol abuse over the past 3 years, may hinder the successful completion of the study. 8. pregnant, lactating women (wcbp) are reluctant to use medically approved contraceptives during treatment and 12 months after treatment.

Keywords: sle telitacicept il-2
immunostimulating interstitial laser thermotherapy in pancreatic cancer

Conditions: Neoplasms Pancreatic

Summary: thermotherapy is a technology aiming at destroying tissue, for example tumor tissue. immunostimulating interstitial laser thermotherapy (imilt) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response. in laboratory animals the imilt method has also been shown to induce a so called abscopal effect. this means that when one tumor is treated with imilt other, untreated, tumors also decrease in size. the purpose of this trial is to evaluate efficiency when it comes to local tumor destruction of the imilt treatment method in patients diagnosed with pancreatic cancer. the purpose is also to investigate the functionality and safety as well as understanding of the subsequent immunological effects. this trial is prospective, open and non-randomized. five patients diagnosed with pancreatic cancer will be treated in this trial, which is estimated to be carried out during a time period of 36 months.


Eligibility criteria:
inclusion criteria: * cytohistological diagnosis of ductal pancreatic adenocarcinoma . * stage iii disease (see above). * the patient is not a candidate for continued chemotherapy or (chemo)radiotherapy due to lack of demonstrable efficiency or to the side effects of the drugs. * age between 18 and 80 years. * anticipated compliance with treatment and follow-up. * double informed consent for both imilt and possible surgery with radical intent (in the event of pre-operative overstaging). * at least a part of the tumor can be treated with imilt without damage to surrounding vital structures. * have an ecog performance status \< 1 (l'eastern cooperative oncology group) exclusion criteria: * not a candidate for laparotomy. * becoming resectable after neoadjuvant chemotherapy. * other simultaneous treatments for the same neoplasm. * simultaneous other malignancies except for basal cell carcinoma. * hiv positive. * active autoimmune disease. * systemic corticosteroid medication. * pregnancy or nursing.

Keywords: hyperthermia, induced laser coagulation laser therapy
prospective evaluation of patients with pleural effusion

Conditions: Pleural Effusion

Summary: having a pleural effusion is a common reason for being hospitalized, as it usually requires in-patient care for invasive diagnostic and therapeutic procedures. specific subtypes of pleural effusion may warrant recurrent admissions, a longer hospital stay and consume more healthcare resources. despite the recent advancement of pleural medicine, better research is increasingly desired to fill the gaps in establishing an early diagnosis and optimal management of pleural effusion from various causes. local data on different aspects of pleural effusion is also lacking.

the aetiologies of pleural effusion range from cardio-respiratory diseases, malignancy, infection to systemic inflammatory conditions. however, data on the exact incidence of individual causes of pleural effusion is inadequate. conflicting results on the aetiologies of pleural effusion were shown in several retrospective and prospective studies based in different geographical regions, which may be explained by the different epidemiology of common diseases in the corresponding areas and patients recruited. despite a common clinical problem, the incidence and aetiology of pleural effusion have not been examined on a population level in hong kong. therefore, a local study is necessary to inform physicians about the disease burden of pleural effusion. the management of pleural disease can be heterogeneous, as reflected by a recent multi-institutional questionnaire study in hong kong. infrequent updates of international guidelines of pleural medicine, lack of an established registry reflecting the patient burden, procedure load and complications may contribute. delayed or suboptimal management of pleural diseases can lead to unnecessary invasive procedures, prolonged hospital stays and even higher mortality rates. a local registry should be established to stocktake and understand diagnostic accuracy and complication rates of pleural procedures and reflects the real-life practice by hospital physicians. this prospective study aims at evaluating the aetiology and management of pleural diseases prospectively. the management by the attending doctors will not be interfered. recruited patients will be divided into subgroups based on their characteristics for further analysis. the data collected from this study will guide the planning of subsequent research to overcome the knowledge and service gap in managing pleural diseases.

Eligibility criteria:
inclusion criteria: * patients hospitalized for pleural effusion. * pleural tapping will be performed for pleural fluid analysis. * aged 18 years old or above exclusion criteria: - failed to obtain informed consent due to the patient's refusal or cognitive impairment
does the use of hemostatic clips during the tumor resection step reduce blood loss during robot-assisted partial nephrectomy?

Conditions: Renal Cancer; Kidney Cancer; Blood Loss

Summary: one challenge of robot-assisted partial nephrectomy (rapn) is to reduce operative blood loss. partial nephrectomy (pn) is a complex surgery that is being made easier by robotic assistance. in this study, we determined whether the use of hemostatic clips during the tumor resection step reduced blood loss during robot-assisted partial nephrectomy. methods: in this retrospective study, we included all consecutive patients who underwent rapn in our university hospital from 2017 to 2019. three experienced surgeons performed the surgery. one surgeon used hemo-lock hemostatic clips during tumor resection to prevent bleeding, and two did not. blood loss in the two groups was compared as the primary endpoint. the duration of clamping, operative time, complications, surgical margins, transfusions, serum creatinine and hemoglobin were compared as secondary endpoints. results: 53 patients were included, 36 in the no-clip group and 17 in the clip group. our two groups were comparable for age, weight, charlson score, tumor size and renal score. there was a significant difference between the two groups for median blood loss 50 ml in the clip group versus 300 ml in the no-clip group (p = 0.0001), whereas median operating time was shorter in the no-clip group, 140 min versus 180 min for the clip group (p = 0.044). no other criterion showed a significant difference. the use of hemo-lock during the tumor resection step in rapn reduced blood loss without impairing renal function. larger studies are still needed to confirm our findings.


Eligibility criteria:
inclusion criteria: * all consecutive patients who underwent robot assisted partial nephrectomy exclusion criteria: * patient off clamping or partial clamping

Keywords: robot assisted partial nephrectomy tips